Sign in
Active, not recruitingPhase 2

Towards a treatment for accelerated maturation in girls testing spiomet.

Key facts

Who runs it
Hospital Universitari De Girona Doctor Josep Trueta
Where
Spain2 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
64 people, planned
Started
2 Dec 2022
Expected to end
30 Sept 2027
Type of study
Interventional
Record updated
27 March 2026

Who can take part

Age
Up to 17 years
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (18)Hide the full registry criteria

Who can take part

  • Age at baseline: 8,0 ≤ age ≤ 9,5 years
  • Birth weight for gestational age (BW-GA) in lower tertile: -2,5 ≤ PN-EG Z-score ≤ 0
  • Body mass index for chronological age at 1st visit in upper tercile: +0 ≤ BMI Z-score ≤ +2,5
  • Progressive advanced puberty [bilateral breast development (Tanner stage 2)] of onset between 7,7 and 9,3 years, with a minimum of 2 months progression
  • White ethnicity
  • Term or late preterm pregnancy: 34 ≤ gestational age < 42 weeks
  • Height at 1st visit: 3rd percentile ≤ height ≤ 97th percentile (adjusted for pubertal stage)
  • Written informed consent of parents or legal guardian

Who cannot take part

  • Excessive delay or advancement of bone age (more than 2 years for chronological age). A bone age radiograph taken within the previous 3 months is acceptable for screening purposes. In this case, a new bone age radiograph should be taken within one week before or after the start of treatment
  • Chronic use of medications, including but not limited to: anticoagulants, anti-inflammatory drugs, oral hypoglycaemics, antiandrogens, oestrogens, progestogens, glucocorticoids, digoxin. Only the use of paracetamol before or during the course of the study will be accepted
  • Previous history of hypersensitivity to any of the medicinal products used in the clinical trial, or to their excipients
  • Any disease which, in the opinion of the investigator, compromises the inclusion of the subject in the clinical trial
  • Known genetic abnormality or chronic conditions, including cardiovascular, neurological, immunological, metabolic, renal, endocrine, digestive, respiratory, or oncological diseases
  • Acute infections or intake of antibiotics or anti-inflammatory drugs within the last 14 days. This criterion applies only to blood collections. Blood draws should be postponed for 14 days after the patient no longer has symptoms and stops taking any of these medications
  • Obesity at the 1st visit (BMI Z-score above +2,5 for chronological age)
  • Tanner's stage of breast development greater than 2
  • Twin pregnancy
  • Evidence of a pathological cause of rapid maturation (including but not limited to: congenital adrenal hyperplasia due to 21-hydroxylase deficiency)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine whether a low-dose combination of generics that collectively reduce ectopic adiposity through different pathways can slow accelerated maturation in early pubertal girls with a history of low prenatal weight (resulting in reduced subcutaneous adipogenesis and reduced capacity for safe lipid storage) and high postnatal weight (resulting in more lipogenesis and more need for lipid storage).

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study.
Record updated
27 March 2026